Therapy Directory

Pomalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention. Browse Pomalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

204

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Multiple Myeloma, Relapsed Refractory Multiple Myeloma
Interventions: Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone; Drug
Lead sponsor: Multiple Myeloma Research Consortium; Network
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: Relapsed Refractory Multiple Myeloma
Interventions: Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide; Drug
Lead sponsor: Multiple Myeloma Research Consortium; Network
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Plantation, Florida • Boston, Massachusetts

Conditions: Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
Interventions: DTRM-555; Drug
Lead sponsor: Zhejiang DTRM Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 5 more

Conditions: Multiple Myeloma
Interventions: SEA-BCMA, dexamethasone, pomalidomide; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 13
States / cities: Palo Alto, California • Aurora, Colorado • Miami, Florida + 10 more

Conditions: Telangiectasia, Hereditary Hemorrhagic
Interventions: Pomalidomide Oral Product, Placebo oral capsule; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Immediate Release (IR) Formulation, Gastro-Retentive (GR) Formulation, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 13
States / cities: West Hollywood, California • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Multiple Myeloma
Interventions: Durvalumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more

Conditions: Myeloma
Interventions: Clarithromycin, Dexamethasone, Ixazomib Citrate, Pomalidomide; Drug
Lead sponsor: Joseph Tuscano; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: La Jolla, California • Orange, California • Sacramento, California

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions: Marizomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: ACY-241, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 11
States / cities: Tucson, Arizona • Denver, Colorado • Miami, Florida + 7 more

Conditions: Multiple Myeloma
Interventions: Alnuctamab, Pomalidomide, Daratumumab, Elotuzumab, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 19 more

About this Pomalidomide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pomalidomide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Pomalidomide clinical trials

Filter and sort this therapy

Live official records

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Myeloma-Developing Regimens Using Genomics (MyDRUG)

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Pomalidomide for the Treatment of Bleeding in HHT

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

Marizomib Central Nervous System (CNS)

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

About this Pomalidomide clinical trials directory page